25 "leukemia" clinical trials found.
-
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
If you or your child have been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL) that has relapsed or is refractory. Relapse means that the cancer has ...
Phase
Interventional
Match Level: Exact
-
AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)
If you are the parent or guardian of a child/adolescent diagnosed with acute lymphoblastic leukemia, your child may qualify to participate in a clinical ...
Phase
Interventional
Match Level: Exact
-
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...
Phase
Interventional
Match Level: Exact
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The purpose of the study is to determine how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive ...
Phase
Interventional
Match Level: Exact
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia (AML) ...
Phase
Interventional
Match Level: Exact
-
A Phase 1 Parallel Open-Label Study of the Safety and Tolerability Pharmacokinetics and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety of ASTX660 alone and in combination with ASTX727 in patients who have acute myeloid leukemia ...
Phase
Interventional
Match Level: Exact
-
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ...
Phase
Interventional
Match Level: Exact
-
A Phase 1 First-in-Human Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of this study is to see if there are doses of JNJ-67571244 (also referred to as ‘study drug’) that are both safe and ...
Phase
Interventional
Match Level: Exact
-
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
The purpose of the study is to evaluate how stopping tyrosine kinase inhibitors (TKI) will affect treatment-free remission in patients with chronic myeloid leukemia (CML) ...
Phase
Interventional
Match Level: Exact
-
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to previous ...
Phase
Interventional
Match Level: Exact
